MeiraGTx to Host a Virtual Research and Development Day on Gene Regulation
December 14, 2021 16:30 ET
|
MeiraGTx
LONDON and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, will host a virtual R&D Day via webcast...
MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
December 07, 2021 07:00 ET
|
MeiraGTx
Clinically meaningful improvements in xerostomia symptoms and disease burden reported in two validated Patient Reported Outcome (PRO) measures6 of the 7 participants through 90-day assessments...
MeiraGTx to Provide a Xerostomia Clinical Program Update and Host a Virtual Research and Development Day on Gene Regulation
November 29, 2021 16:30 ET
|
MeiraGTx
LONDON and NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference...
MeiraGTx Reports Third Quarter 2021 Financial and Operational Results
November 10, 2021 08:00 ET
|
MeiraGTx
LONDON and NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results...
MeiraGTx to Participate in Upcoming Virtual Investor Conferences
November 09, 2021 16:30 ET
|
MeiraGTx
LONDON and NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria...
MeiraGTx Announces the Presentation of Two Novel Inherited Retinal Disease (IRD) Programs and Riboswitch Gene Regulation Platform at the European Society of Gene and Cell Therapy (ESGCT) 2021 Annual Congress
October 19, 2021 08:30 ET
|
MeiraGTx
Three Poster Presentations Highlight Versatility and Novelty of MeiraGTx’s Gene Therapy Development Platforms Novel Synthetic Riboswitch Platform Reversibly Regulates Gene Expression to High...
MeiraGTx to Present at the Chardan 5th Annual Genetic Medicines Conference
September 28, 2021 16:30 ET
|
MeiraGTx
LONDON and NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria...
MeiraGTx Announces Data at EURETINA 2021 Virtual Meeting Demonstrating Reversal of Disease Progression Following Treatment with AAV5-RPGR in X-Linked Retinitis Pigmentosa
September 09, 2021 08:30 ET
|
MeiraGTx
LONDON and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced new data from...
MeiraGTx Reports Second Quarter 2021 Financial and Operational Results
August 11, 2021 08:00 ET
|
MeiraGTx
LONDON and NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results...
MeiraGTx Reports First Quarter 2021 Financial and Operational Results
May 11, 2021 08:00 ET
|
MeiraGTx
LONDON and NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the...